Skip to main content

Geisinger one of 15 sites working to standardize collection and measurement of data on rare genetic disorders

DANVILLE, Pa. – Geisinger, along with two university partners, has been awarded an $8.5 million, five-year grant from the National Institutes of Health (NIH) to study the role of genetics in neuropsychiatric disorders, including autism spectrum disorder, schizophrenia, and bipolar disorder.

Geisinger was awarded the grant with the University of Washington in Seattle and Washington University in St. Louis. The project is one of five funded through the National Institute of Mental Health’s newly established Mental Health Rare Genetic Disease Network (MHRGDN), which includes researchers at 15 sites across the United States. Geisinger’s grant is co-funded by the Eunice Kennedy Shriver National Institute for Child Health and Human Development. 

Geisinger’s primary investigators are Christa L. Martin, Ph.D., associate chief scientific officer and director of Geisinger’s Autism & Developmental Medicine Institute, and David H. Ledbetter, Ph.D., Geisinger’s executive vice president and chief scientific officer.

Researchers from the 15 sites in the MHRGDN network will recruit patients with known genetic causes of neuropsychiatric disorders. They will then conduct in-depth genomic and clinical assessments of patients and their family members to explore the impact of genetics on neuropsychiatric disorders. The standardized data will be made available to research facilities throughout the country through the National Institute of Mental Health to accelerate further research.

The main genetic changes to be studied are copy number variants (CNVs) of 1q21.1, 16p11.2, 15q13.3, 22q11.2, and those involving the CHD8 gene.

“Our understanding of the genetic causes of neuropsychiatric disorders is growing every day, but we still have a lot to learn,” said Dr. Martin. “We can now identify a genetic cause in up to 40 percent of children with neuropsychiatric disorders. This study will gather detailed descriptions of the clinical symptoms of these individuals to discover how to improve their medical care and outcomes.”

“This initiative allows Geisinger patients and their families to be part of something significant beyond our health system,” said Dr. Ledbetter. “Research institutions across the U.S. have been collecting genetic data for many years, while discussing ways to streamline the process. Through this project, we will begin to harmonize our collection of this data, which will ultimately improve the clinical care we provide to our patients.”

 

About Geisinger
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.

geisinger placeholder

For media inquiries:

Ashley Andyshak Hayes
Media Specialist
Marketing & Communications

717-972-4043
arandyshakhayes@geisinger.edu